Latest News

Rezatapopt hit a 46% ORR in TP53 Y220C–mutated ovarian cancer in the PYNNACLE trial, with an FDA filing expected in Q1 2027.

FDA grants breakthrough status to JBS-003 F-MISO PET imaging, aiming to personalize radiation in HPV-positive throat cancer by safely reducing dose for nonhypoxic tumors.

Phase 3 SANOVO shows savolitinib plus osimertinib extends PFS in first-line EGFR-mutant, MET-high NSCLC, hinting at OS gains.

The phase 2b VISUALIZE trial found abenacianine identified a clinically significant event in 45% of lung cancer surgeries, says Gavin M. Wright, MBBS, FRACS, PhD.

Learn how oncologists spot burnout early and cut it with smarter workflows, PTO coverage, supportive leadership, and AI-powered documentation.

The application for the selinexor combination is supported by data from the phase 3 SENTRY trial.

The OS findings follow the recent FDA approval of zanidatamab with or without tislelizumab in HER2-positive gastroesophageal cancer.

FDA aligns on IDE849 phase 3 trial in post-tarlatamab ES-SCLC, testing DLL3 ADC vs chemo, aiming for accelerated approval.

August 2026 FDA oncology updates: iberdomide, zanidatamab, and daraxonrasib win approvals as fast-track designations accelerate targeted pipelines.

The approval marks the first new agent specifically approved for essential thrombocythemia in the US in nearly 30 years.

ASCO's updated guideline on breast cancer follow-up recommends risk-based surveillance intensity and selective mammography rather than one-size-fits-all follow-up.

The approval is primarily supported by the phase 3 VERIFY study.

Almost one-third of patients became newly eligible for treatment after identification of a previously undetected druggable mutation.

FDA clears IND for ADI-212, an off-the-shelf PSMA-targeted gamma-delta CAR T for metastatic castration-resistant prostate cancer, as phase 1/2 trial readies 2026 enrollment.

During a live event, Casey L. O'Connell, MD, and participants considered how white blood cell count may factor into risk assessment for polycythemia vera.

Shubham Pant, MD, MBBS, explains the significance of the FDA approval of daraxonrasib for mPDAC.

Varsetatug masetecan is a first-in-class ADC that pairs a monoclonal antibody against EpCAM with a topoisomerase 1 inhibitor payload.

Celcuity seeks FDA expansion for gedatolisib combos in PIK3CA-mutant HR+/HER2– metastatic breast cancer, after VIKTORIA-1 shows longer PFS than alpelisib.

ERAS-0015 is being tested in AURORAS-1, an open-label study enrolling patients with RAS-mutant solid tumors.

The assays are now approved to assess HER2 status in gastric, gastroesophageal junction, and esophageal adenocarcinoma.

The LRRC15-targeting antibody-drug conjugate will be investigated in a first-in-human trial later this year.

The final recommendations were directly shaped by data from 36 published articles.

Phase 2 data show an outpatient fixed-duration combo yields 79% complete responses and 18.6-month PFS in relapsed mantle cell lymphoma.

The approval of daraxonrasib in pancreatic cancer is supported by results from the phase 3 RASolute 302 trial.

FDA issues third CRL for lower-dose dasatinib Dasynoc over manufacturing, not data, as Xspray races to resubmit amid PPI absorption benefits.

An exploratory analysis from the SECOMBIT trial showed differences in outcomes based on thymidine kinase activity in BRAF-mutated melanoma treated with immunotherapy and targeted therapy.

The benefit of daraxonrasib in PDAC may be overstated in RASolute 302 due to informative censoring.

The MODeFIRe-1 trial of MRT-2359 plus apalutamide will focus on AR mutations in metastatic castration-resistant prostate cancer.

In an interview, Surbhi Sidana, MD, explores the significance of iberdomide's FDA approval and how this agent fits into the growing array of novel multiple myeloma therapies.

The FDA approved 2 zanidatamab-based regimens for first-line HER2-positive gastroesophageal adenocarcinoma, based on phase 3 HERIZON-GEA-01 data.

The sBLA for dostarlimab in dMMR/MSI-H rectal cancer is based on the AZUR-1 trial.